Format
Sort by
Items per page

Send to

Choose Destination

Best matches for androgens AND hypogonadism AND prostate AND testosterone:

The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. Klap J et al. J Urol. (2015)

Male hypogonadism. Basaria S et al. Lancet. (2014)

Androgens and prostate cancer; pathogenesis and deprivation therapy. Grossmann M et al. Best Pract Res Clin Endocrinol Metab. (2013)

Search results

Items: 1 to 20 of 532

1.

The History of Testosterone and the Evolution of its Therapeutic Potential.

Morgentaler A, Traish A.

Sex Med Rev. 2018 Apr 13. pii: S2050-0521(18)30040-4. doi: 10.1016/j.sxmr.2018.03.002. [Epub ahead of print] Review.

PMID:
29661690
2.

Shifting the Paradigm of Testosterone Replacement Therapy in Prostate Cancer.

Bell MA, Campbell JD, Joice G, Sopko NA, Burnett AL.

World J Mens Health. 2018 May;36(2):103-109. doi: 10.5534/wjmh.170007. Epub 2018 Mar 22. Review.

3.

Evaluation and Management of Testosterone Deficiency: AUA Guideline.

Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV, Lewis RW.

J Urol. 2018 Mar 28. pii: S0022-5347(18)42817-0. doi: 10.1016/j.juro.2018.03.115. [Epub ahead of print]

PMID:
29601923
4.

Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pAR<sup>ser81</sup> and CDK1 signaling: biological implications for men treated with testosterone replacement therapy.

Gravina GL, Marampon F, Sanità P, Festuccia C, Forcella C, Scarsella L, Jitariuc A, Vetuschi A, Sferra R, Colapietro A, Carosa E, Dolci S, Lenzi A, Jannini EA.

Oncotarget. 2017 Nov 30;8(69):113792-113806. doi: 10.18632/oncotarget.22776. eCollection 2017 Dec 26.

5.

The safety of available treatments of male hypogonadism in organic and functional hypogonadism.

Corona G, Rastrelli G, Reisman Y, Sforza A, Maggi M.

Expert Opin Drug Saf. 2018 Mar;17(3):277-292. doi: 10.1080/14740338.2018.1424831. Epub 2018 Jan 15. Review.

PMID:
29334271
6.

British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice.

Hackett G, Kirby M, Edwards D, Jones TH, Wylie K, Ossei-Gerning N, David J, Muneer A.

J Sex Med. 2017 Dec;14(12):1504-1523. doi: 10.1016/j.jsxm.2017.10.067. Review.

7.

Testosterone Therapy: Review of Clinical Applications.

Petering RC, Brooks NA.

Am Fam Physician. 2017 Oct 1;96(7):441-449. Review.

PMID:
29094914
8.

Low serum testosterone is a predictor of high-grade disease in patients with prostate cancer.

Albuquerque GAML, Guglielmetti GB, Barbosa JABA, Pontes J Jr, Fazoli AJC, Cordeiro MD, Coelho RF, Carvalho PA, Gallucci FP, Padovani GP, Park R, Cury J, Nonemacher H, Srougi M, Nahas WC.

Rev Assoc Med Bras (1992). 2017 Aug;63(8):704-710. doi: 10.1590/1806-9282.63.08.704.

9.

Estradiol for the mitigation of adverse effects of androgen deprivation therapy.

Russell N, Cheung A, Grossmann M.

Endocr Relat Cancer. 2017 Aug;24(8):R297-R313. doi: 10.1530/ERC-17-0153. Epub 2017 Jun 30. Review.

10.

Testosterone Therapy on Active Surveillance and Following Definitive Treatment for Prostate Cancer.

Golla V, Kaplan AL.

Curr Urol Rep. 2017 Jul;18(7):49. doi: 10.1007/s11934-017-0695-6. Review.

11.

Clinical significance of androgen secretion disorders in men with a malignancy.

Wiechno PJ, Poniatowska GM, Michalski W, Kucharz J, Sadowska M, Jonska-Gmyrek J, Nietupski K, Rzymowska J, Demkow T.

Med Oncol. 2017 Jul;34(7):123. doi: 10.1007/s12032-017-0982-6. Epub 2017 Jun 1. Review.

12.

External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer.

Pompe RS, Karakiewicz PI, Zaffuto E, Smith A, Bandini M, Marchioni M, Tian Z, Leyh-Bannurah SR, Schiffmann J, Delouya G, Lambert C, Bahary JP, Beauchemin MC, Barkati M, Ménard C, Graefen M, Saad F, Tilki D, Taussky D.

J Sex Med. 2017 Jul;14(7):876-882. doi: 10.1016/j.jsxm.2017.04.675. Epub 2017 May 22.

PMID:
28546065
13.

The prostate after castration and hormone replacement in a rat model: structural and ultrastructural analysis.

Felix-Patrício B, Miranda AF, Medeiros JL Jr, Gallo CBM, Gregório BM, Souza DB, Costa WS, Sampaio FJB.

Int Braz J Urol. 2017 Sep-Oct;43(5):957-965. doi: 10.1590/S1677-5538.IBJU.2016.0484.

14.

[Hypogonadism in patients with testicular tumors and prostate cancer].

Radko M, Syryło T, Zieliński H.

Wiad Lek. 2017;70(1):81-84. Review. Polish.

PMID:
28343199
15.

'Forever Young'-Testosterone replacement therapy: a blockbuster drug despite flabby evidence and broken promises.

Busnelli A, Somigliana E, Vercellini P.

Hum Reprod. 2017 Apr 1;32(4):719-724. doi: 10.1093/humrep/dex032.

16.

Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open-label studies.

Belkoff L, Brock G, Carrara D, Neijber A, Ando M, Mitchel J.

Andrologia. 2018 Feb;50(1). doi: 10.1111/and.12801. Epub 2017 Mar 10.

PMID:
28295450
17.

Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register.

Yassin A, Salman M, Talib RA, Yassin DJ.

Aging Male. 2017 Jun;20(2):125-133. doi: 10.1080/13685538.2017.1298584. Epub 2017 Mar 10.

PMID:
28282997
19.

EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM.

Cunningham G, Belkoff L, Brock G, Efros M, Gittelman M, Carrara D, Neijber A, Ando M, Mitchel J.

Endocr Pract. 2017 May;23(5):557-565. doi: 10.4158/EP161665.OR. Epub 2017 Feb 22.

PMID:
28225313
20.

Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy.

Salman M, Yassin DJ, Shoukfeh H, Nettleship JE, Yassin A.

Aging Male. 2017 Mar;20(1):45-48. doi: 10.1080/13685538.2016.1260107. Epub 2017 Jan 13.

PMID:
28084147

Supplemental Content

Loading ...
Support Center